On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Sir Gregory Winter FRS is Master of Trinity College Cambridge and was until recently a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge. He is a scientist, inventor and entrepreneur. He is a pioneer of the science of protein engineering, and in particular of technologies for making pharmaceutical antibodies. Such antibodies have proved useful for treatment of cancer and immune disorders, and now comprise many of the world’s top selling pharmaceutical drugs. In order to see his technologies applied, Sir Gregory founded Cambridge Antibody Technology and Domantis (both acquired in 2006 by AstraZeneca and GSK respectively), and most recently Bicycle Therapeutics, which is developing bicyclic peptides with chemical warheads for treatment of cancer.
